pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 14·1 min read
save

Pharma firms must complete extensive paperwork and undergo monitoring to qualify for a 20% tariff reduction

May 14, 2026·read at Endpoints ↗RegulatoryNeutral

The Department of Commerce announced that pharmaceutical manufacturers must complete a detailed application to qualify for a reduced 20% tariff rate.

The requirement follows an executive order signed by President Donald Trump, which aims to tighten oversight of tariff concessions.

Companies will be required to submit extensive paperwork and will be subject to ongoing monitoring by the Commerce Department to ensure compliance.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Drugmakers have to go through rigorous tests to get a lower tariff rate”

read at Endpoints ↗
84 words · retrieved May 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 38m ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints
  • 2h agoGilead’s pill posts stronger colitis remission rates than EntyvioEndpoints
  • 2h agoEyePoint's Phase 3 failure; Lilly's China drug delivery dealEndpoints
  • 3h agoMerck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3BEndpoints
  • 4h agoSanofi taps new startup ScionxBio for long-acting RNAEndpoints